MA42655A - Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer - Google Patents
Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancerInfo
- Publication number
- MA42655A MA42655A MA042655A MA42655A MA42655A MA 42655 A MA42655 A MA 42655A MA 042655 A MA042655 A MA 042655A MA 42655 A MA42655 A MA 42655A MA 42655 A MA42655 A MA 42655A
- Authority
- MA
- Morocco
- Prior art keywords
- aminopyridin
- methylpyrrolidine
- benzofuran
- fluorophenyl
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562206472P | 2015-08-18 | 2015-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42655A true MA42655A (fr) | 2021-04-07 |
Family
ID=56799634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042655A MA42655A (fr) | 2015-08-18 | 2016-08-18 | Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US10363247B2 (fr) |
EP (1) | EP3337797A1 (fr) |
JP (1) | JP2018528196A (fr) |
CN (1) | CN108137563A (fr) |
AU (1) | AU2016308829A1 (fr) |
CA (1) | CA2995380A1 (fr) |
EA (1) | EA201890524A1 (fr) |
HK (1) | HK1255438A1 (fr) |
IL (1) | IL257422A (fr) |
MA (1) | MA42655A (fr) |
MX (1) | MX2018001979A (fr) |
WO (1) | WO2017031323A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201690153A1 (ru) * | 2013-07-03 | 2016-06-30 | Кариофарм Терапевтикс, Инк. | Замещенные бензофуранильные и бензоксазолильные соединения и их применения |
WO2015042414A1 (fr) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Composés multicycliques et leurs procédés d'utilisation |
MA42655A (fr) | 2015-08-18 | 2021-04-07 | Karyopharm Therapeutics Inc | Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer |
US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
CN111171233B (zh) * | 2020-01-17 | 2023-03-31 | 吉林师范大学 | 一种新型磁性薄层印迹膜的制备方法及用途 |
CN115581692B (zh) * | 2020-02-26 | 2023-10-17 | 上海科技大学 | 苏木的活性成分在抗冠状病毒中的应用 |
CN114507215A (zh) * | 2020-11-14 | 2022-05-17 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
DE19818044A1 (de) | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
CA2453294A1 (fr) | 2001-07-19 | 2003-01-30 | Paolo Pevarello | Derives de phenylacetamido-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux |
EP1348434A1 (fr) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Utilisation de pyridylamides comme inhibiteurs de l'angiogenèse |
US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
EP1627873A4 (fr) * | 2003-05-29 | 2007-12-05 | New Ind Res Organization | Compose a base de benzofurane et composition medicinale contenant ce compose |
JP4709757B2 (ja) | 2003-08-07 | 2011-06-22 | ニツポネツクス・インコーポレーテツド | 過剰増殖性障害の処置に有用なベンゾフラン誘導体 |
US7368476B2 (en) | 2004-04-07 | 2008-05-06 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
JP4101852B2 (ja) | 2004-05-26 | 2008-06-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物 |
JPWO2006038606A1 (ja) | 2004-10-05 | 2008-05-15 | 塩野義製薬株式会社 | ビアリール誘導体 |
JPWO2006054793A1 (ja) | 2004-11-19 | 2008-06-05 | 財団法人新産業創造研究機構 | ベンゾフラン化合物、およびそれを含有してなる医薬組成物 |
BRPI0608659A2 (pt) | 2005-04-06 | 2010-11-30 | Astrazeneca Ab | composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
CN101180283A (zh) | 2005-04-22 | 2008-05-14 | 惠氏公司 | 二氢苯并呋喃衍生物和其用途 |
US20080020413A1 (en) | 2006-03-29 | 2008-01-24 | Columbia University | Crystalline visfatin and methods therefor |
WO2008026018A1 (fr) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | Nouveau procédé pour le traitement des maladies inflammatoires |
EP2003118A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2 |
US8173677B2 (en) | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
US8211912B2 (en) | 2007-09-26 | 2012-07-03 | Gemin X Pharmaceuticals Canada | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor |
EP2098231A1 (fr) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Utilisation des inhibiteurs de la formation de NAD pour le traitement de lesions d'ischemie-reperfusion |
FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
KR20130044382A (ko) | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | 화합물 및 그의 치료 용도 |
WO2012150952A1 (fr) | 2011-05-04 | 2012-11-08 | Forma Tm, Llc | Nouveaux composés et compositions utilisés dans l'inhibition de nampt |
EP2739144A4 (fr) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | Composés et ses utilisations thérapeutiques |
WO2013082150A1 (fr) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Inhibiteurs à petite molécule de nicotinamide phosphoribosyltransférase (nampt) |
WO2014074715A1 (fr) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Dérivés d'amide cyclopropyle |
EP2925750A1 (fr) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Composés 2,3-dihydrobenzofuranyle substitués et leurs utilisations |
WO2014111871A1 (fr) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | Dérivés de 4,5-dihydroisoxazole utilisés comme inhibiteurs de nampt |
EA201690153A1 (ru) * | 2013-07-03 | 2016-06-30 | Кариофарм Терапевтикс, Инк. | Замещенные бензофуранильные и бензоксазолильные соединения и их применения |
WO2015042414A1 (fr) * | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Composés multicycliques et leurs procédés d'utilisation |
WO2015054060A1 (fr) | 2013-10-09 | 2015-04-16 | Eli Lilly And Company | Nouveaux composés de pyridyloxyacétyl tétrahydroisoquinoline utiles en tant qu'inhibiteurs de nampt |
US20170369470A1 (en) | 2014-12-16 | 2017-12-28 | Karyopharm Therapeutics Inc. | Cyclic Compounds and Uses Thereof |
US20190218207A1 (en) | 2015-08-17 | 2019-07-18 | Karyopharm Therapeutics Inc. | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators |
US20180244660A1 (en) | 2015-08-17 | 2018-08-30 | Karyopharm Therapeutics Inc. | Cyclopropylderivatives and their use as kinase inhibitors |
MA42655A (fr) | 2015-08-18 | 2021-04-07 | Karyopharm Therapeutics Inc | Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer |
US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
US20190002448A1 (en) | 2015-12-31 | 2019-01-03 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
-
2016
- 2016-08-18 MA MA042655A patent/MA42655A/fr unknown
- 2016-08-18 AU AU2016308829A patent/AU2016308829A1/en not_active Abandoned
- 2016-08-18 MX MX2018001979A patent/MX2018001979A/es unknown
- 2016-08-18 US US15/753,897 patent/US10363247B2/en active Active
- 2016-08-18 EA EA201890524A patent/EA201890524A1/ru unknown
- 2016-08-18 CN CN201680060621.6A patent/CN108137563A/zh active Pending
- 2016-08-18 JP JP2018509622A patent/JP2018528196A/ja active Pending
- 2016-08-18 WO PCT/US2016/047566 patent/WO2017031323A1/fr active Application Filing
- 2016-08-18 CA CA2995380A patent/CA2995380A1/fr not_active Abandoned
- 2016-08-18 EP EP16756931.8A patent/EP3337797A1/fr not_active Withdrawn
-
2018
- 2018-02-08 IL IL257422A patent/IL257422A/en unknown
- 2018-11-15 HK HK18114602.1A patent/HK1255438A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2995380A1 (fr) | 2017-02-23 |
WO2017031323A1 (fr) | 2017-02-23 |
CN108137563A (zh) | 2018-06-08 |
AU2016308829A1 (en) | 2018-03-08 |
JP2018528196A (ja) | 2018-09-27 |
HK1255438A1 (zh) | 2019-08-16 |
EP3337797A1 (fr) | 2018-06-27 |
IL257422A (en) | 2018-04-30 |
US20180235948A1 (en) | 2018-08-23 |
MX2018001979A (es) | 2019-04-25 |
US10363247B2 (en) | 2019-07-30 |
EA201890524A1 (ru) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42655A (fr) | Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer | |
MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
IL264049A (en) | Compounds, preparations and methods for treating the disease | |
IL264156A (en) | Compounds, preparations and methods for treating the disease | |
IL253945B (en) | kdm1a inhibitors to treat the disease | |
MA55694A (fr) | Méthodes de conditionnement de patients pour la thérapie cellulaire t | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
EA201691997A1 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
TR201909353T4 (tr) | Multipl skleroz tedavisi. | |
IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
IL272992A (en) | Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide | |
IL274747A (en) | FXR agonists for the treatment of liver diseases | |
EP3749647C0 (fr) | Dérivés de n-(5-(phényl)-1h-pyrazol-3-yl)-1h-indol-5-amine en tant qu'inhibiteurs tnik pour le traitement du cancer | |
MA51688A (fr) | Protéines prohémostatiques pour le traitement de saignement | |
MA49375A (fr) | Composition pour le traitement de la blépharite | |
DK3515418T3 (da) | Anvendelse af c-met-inhibitorer til behandling af cancere, der omfatter met-mutationer | |
FR3072015B1 (fr) | Implant medical pour arthrodese | |
EP3529243C0 (fr) | (z)-3-(2-(5-bromo-1h-indole-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile pour le traitement de l'endométriose |